Amersham's Ceretec used for Alzheimer's detection
This article was originally published in Clinica
Executive Summary
Latest results from a UK study show that brain scanning combined with functional imaging of blood flow using SPECT with Amersham International's technetium-99m agent, Ceretec, provides enhanced accuracy in diagnosing Alzheimer's disease. The technology, developed by the Oxford Project to Investigate Memory and Ageing (OPTIMA), is being used in hospitals in the UK, France, Germany, South Africa and Australia, Amersham's medical director, Dr Rhiannon Rowsell, told Clinica.